53
Research Trials
20
Peer-reviewed publications
16
Clinical Conditions
Hyfe pilot study tests a digital therapeutic combining passive cough monitoring with behavioral suppression techniques delivered through the CoughPro app.
This narrative review by Hyfe's R&D team makes the case that continuous cough monitoring (CCM), powered by acoustic AI, transforms cough from a subjective symptom into a quantifiable digital biomarker.
Independent ERS 2025 NeuroCOUGH trial uses the Hyfe Cough Tracker to test feasibility of studying azithromycin's effect on cough and oesophageal motility.
Independent ERS 2025 trial uses the Hyfe Cough Tracker to show azithromycin reduces objective cough frequency by week one in chronic respiratory disease.
18.11.2025
This investigator-led pilot study from a Spanish nursing and digital health team explored whether continuous cough monitoring can serve as an objective tolerability marker for inhaled antibiotic therapy in chronic bronchial infection, a setting where adverse effects often surface only through patient self-report. Eight patients, predominantly women with bronchiectasis colonised by Pseudomonas aeruginosa or Haemophilus influenzae, were monitored with the Hyfe Cough Monitoring System for one week before and four weeks after starting inhaled colistin or gentamicin. Individual cough trajectories diverged sharply: three patients improved, three worsened, and two did not tolerate treatment, with one showing a progressive doubling of cough rate during therapy that resolved after discontinuation. The findings position continuous cough monitoring as a candidate objective marker of inhaled antibiotic tolerance, capable of flagging adverse responses earlier than symptom-based assessment alone and supporting more personalised treatment decisions.
